GlaxoSmithKline plc (GSK)
-NYSE 52.66 
0.45(0.86%) 11:46AM EDT - Nasdaq Real Time Price
| Prev Close: | 52.21 |
|---|
| Open: | 52.01 |
|---|
| Bid: | 52.68 x 100 |
|---|
| Ask: | 52.69 x 200 |
|---|
| 1y Target Est: | 48.56 |
|---|
| Beta: | 0.57 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 52.01 - 52.81 |
|---|
| 52wk Range: | 41.68 - 52.81 |
|---|
| Volume: | 1,313,667 |
|---|
| Avg Vol (3m): | 2,758,760 |
|---|
| Market Cap: | 127.54B |
|---|
| P/E (ttm): | 19.26 |
|---|
| EPS (ttm): | 2.74 |
|---|
| Div & Yield: | 2.20 (4.20%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Top 5 Dividend Companies of Warren Buffettat Motley Fool(Tue 7:10AM EDT)
- Theravance pullback on Elan bid a buying opportunity, says Piper Jaffrayat theflyonthewall.com(Tue 7:07AM EDT)
- From Novel Research to Innovative Medicines: GlaxoSmithKline Launches Discovery Fast Track Competition for Academic ResearchersBusiness Wire(Tue 7:02AM EDT)
- The 3 Deadliest Diseases in the U.S.at Motley Fool(Mon, May 20)
- This Week in Biotechat Motley Fool(Sat, May 18)
- 3 Most Important Upcoming FDA Decisions of 2013at Motley Fool(Fri, May 17)
- The Billion Dollar COPD Deal: Who Gains The Most?at Seeking Alpha(Fri, May 17)
- Cheerleaders: Look Beyond Pharma For JobsYCharts(Thu, May 16)
- Time To Show Optimism For Stocksat Seeking Alpha(Thu, May 16)
- Prestige Slides On Revenue Miss But Vows More Buysat Investor's Business Daily(Thu, May 16)
- Theravance Looks to Reward Shareholders by Splitting Into Two Distinct Companiesat Motley Fool(Wed, May 15)
- Amicus Therapeutics: The Good And The Badat Seeking Alpha(Wed, May 15)
- Is Vivus a Buy at These Prices?at Wall St. Cheat Sheet(Wed, May 15)
- Is AstraZeneca Gearing Up for a Shopping Spree?at Motley Fool(Wed, May 15)
- Aveo Screwed Up but Its Kidney Cancer Drug Is Realat TheStreet(Wed, May 15)
Key Statistics
| Forward P/E (1 yr): | 12.46 |
|---|
| P/S (ttm): | 3.00 |
|---|
| Ex-Dividend Date: | 08-May-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.91 |
|---|
| Quarterly EPS Est
(Mar-13)
: | N/A |
|---|
| Mean Recommendation*: | 2.9 |
|---|
| PEG Ratio (5 yr expected): | 4.13 |
|---|
Business Summary
GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide.
View More